MX2019009020A - Metodo para reducir la neutropenia. - Google Patents

Metodo para reducir la neutropenia.

Info

Publication number
MX2019009020A
MX2019009020A MX2019009020A MX2019009020A MX2019009020A MX 2019009020 A MX2019009020 A MX 2019009020A MX 2019009020 A MX2019009020 A MX 2019009020A MX 2019009020 A MX2019009020 A MX 2019009020A MX 2019009020 A MX2019009020 A MX 2019009020A
Authority
MX
Mexico
Prior art keywords
neutropenia
reduce
reduce neutropenia
plinabulin
docetaxel
Prior art date
Application number
MX2019009020A
Other languages
English (en)
Spanish (es)
Inventor
Huang Lan
Mohanlal Ramon
Kenneth Lloyd George
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of MX2019009020A publication Critical patent/MX2019009020A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2019009020A 2017-02-01 2018-02-01 Metodo para reducir la neutropenia. MX2019009020A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762453375P 2017-02-01 2017-02-01
US201862621533P 2018-01-24 2018-01-24
PCT/US2018/016498 WO2018144764A1 (en) 2017-02-01 2018-02-01 Method of reducing neutropenia

Publications (1)

Publication Number Publication Date
MX2019009020A true MX2019009020A (es) 2019-11-12

Family

ID=63040105

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009020A MX2019009020A (es) 2017-02-01 2018-02-01 Metodo para reducir la neutropenia.
MX2022010805A MX2022010805A (es) 2017-02-01 2019-07-30 Metodo para reducir la neutropenia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010805A MX2022010805A (es) 2017-02-01 2019-07-30 Metodo para reducir la neutropenia.

Country Status (15)

Country Link
US (2) US11400086B2 (enExample)
EP (1) EP3576733A4 (enExample)
JP (2) JP2020514412A (enExample)
KR (2) KR20240110997A (enExample)
CN (1) CN110381938A (enExample)
AU (1) AU2018217120B2 (enExample)
BR (1) BR112019015974A2 (enExample)
CA (1) CA3052190A1 (enExample)
CL (1) CL2019002127A1 (enExample)
IL (1) IL268305B2 (enExample)
MX (2) MX2019009020A (enExample)
MY (1) MY201811A (enExample)
PH (1) PH12019501763A1 (enExample)
SG (1) SG11201907023UA (enExample)
WO (1) WO2018144764A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
AU2016291708B2 (en) 2015-07-13 2020-12-24 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
EP3413885A4 (en) 2016-02-08 2019-09-18 Beyondspring Pharmaceuticals, Inc. COMPOSITIONS WITH TUCARESOL OR ITS ANALOG
SG11201810872UA (en) * 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
KR20200116477A (ko) * 2018-02-01 2020-10-12 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 및 g-csf 제제의 투여를 통해 화학요법-유도된 호중구감소증을 감소시키기 위한 조성물 및 방법
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
JP2022552011A (ja) * 2019-10-15 2022-12-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 鉄障害を処置するための方法及び組成物
WO2022040073A1 (en) * 2020-08-18 2022-02-24 Spectrum Pharmaceuticals, Inc. Novel methods of treating neutropenia using g-csf protein complex
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
WO2023274316A1 (zh) * 2021-06-29 2023-01-05 深圳华泓海洋生物医药有限公司 氘代普那布林在制备治疗中性粒细胞减少症药物中的应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164B1 (enExample) 1970-12-29 1975-04-10
ZM5780A1 (en) 1979-06-29 1983-11-21 Wellcome Found Pharmaceutical ethers,preparation,use and intermediates therefor and their preparation
EP0054924B1 (en) 1980-12-18 1986-08-06 The Wellcome Foundation Limited Pharmaceutical compounds, their preparation and use
JPS58167304A (ja) 1982-03-24 1983-10-03 松下電器産業株式会社 ごみ処理装置
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
ES2096215T3 (es) 1992-10-01 1997-03-01 Wellcome Found Tucaresol como agente inmunopotenciador.
DE69320206T2 (de) 1992-11-27 1999-02-11 Napro Biotherapeutics Inc Paclitaxel enthaltende injizierbare zusammensetzung
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
MXPA00004919A (es) 1997-11-21 2002-10-17 Euro Celtique Sa 2-aminoacetamidas sustituidas y uso de las mismas.
AU747987B2 (en) 1998-01-29 2002-05-30 Aventis Pharmaceuticals Inc. Method for preparing an N-((aliphatic or aromatic)carbonyl)-2-aminoacetamide compound and a cyclyzed compound
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
US6333323B1 (en) 1998-03-26 2001-12-25 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
DE60033293D1 (de) 1999-08-23 2007-03-22 Dana Farber Cancer Inst Inc Neue b7-4 moleküle und deren verwendungen
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
NZ519989A (en) 2000-01-18 2004-05-28 Nereus Pharmaceuticals Inc Cell division inhibitors and process for producing the same
AU2001245823A1 (en) 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
EP1282609B1 (en) 2000-05-09 2008-12-17 AngioRx Corporation Piperazinedione compounds
US6583143B2 (en) 2000-12-28 2003-06-24 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
MXPA04010640A (es) 2002-05-17 2005-08-16 Aventis Pharma Sa Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario.
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7064201B2 (en) 2002-08-02 2006-06-20 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
BRPI0506655A (pt) 2004-02-04 2007-05-08 Nereus Pharmaceuticals Inc dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
EA010198B1 (ru) 2004-04-19 2008-06-30 Крка, Товарна Здравил, Д.Д., Ново Место Способы получения полиморфной формы i гидросульфата клопидогрела
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
EP1926724A1 (en) 2005-09-21 2008-06-04 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2481418A1 (en) 2007-02-15 2012-08-01 MannKind Corporation A method for enhancing T cell response
WO2008128169A1 (en) 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
SG185954A1 (en) 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
CN101909693A (zh) 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
EA201190079A1 (ru) 2009-01-16 2013-02-28 Тева Фармасьютикал Индастриз, Лтд. Новые стабильные составы рекомбинантного альбумина человека-гранулоцитарного колониестимулирующего фактора человека
CA2754217A1 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
ES2543280T3 (es) 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
JP5855568B2 (ja) 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
US20120114658A1 (en) 2009-09-15 2012-05-10 John Ryan Treatment of cancer
JP2013508415A (ja) 2009-10-23 2013-03-07 マンカインド コーポレイション 癌の免疫療法、および治療の方法
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
EP2542699A4 (en) 2010-03-03 2013-10-02 Targeted Molecular Diagnostics Llc METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CA2799653A1 (en) 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US20120214679A1 (en) 2010-11-29 2012-08-23 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
AU2012344676A1 (en) 2011-11-28 2014-06-19 National Research Council Of Canada Paclitaxel response markers for cancer
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
WO2013124867A1 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
EA029382B1 (ru) 2012-05-09 2018-03-30 Кантекс Фармасьютикалз, Инк. Лечение миелосупрессии
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
KR20210008155A (ko) 2012-08-30 2021-01-20 암젠 인크 단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
BR112015007144A2 (pt) * 2012-10-04 2017-12-12 Ab Science uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2014130657A1 (en) 2013-02-20 2014-08-28 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
CA2905418C (en) 2013-03-13 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP3593839A1 (en) 2013-03-15 2020-01-15 Amgen Inc. Drug cassette
JP6526627B2 (ja) 2013-04-24 2019-06-05 テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド 組織解析用の磁気共鳴マップ
JP6603209B2 (ja) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾
KR20160013049A (ko) 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
JP6205192B2 (ja) 2013-07-02 2017-09-27 テルモ株式会社 薬液充填済み容器体を収容した包装体
LT3838271T (lt) * 2013-07-12 2025-11-10 Padidėjusio eozinofilų ir (arba) bazofilų kiekio gydymas
JP6311097B2 (ja) 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
CA2926771C (en) * 2013-10-11 2022-07-05 Beyondspring Pharmaceuticals, Inc. Cancer treatment with combination of plinabulin and taxane
JP2016540042A (ja) 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
US10607717B2 (en) 2013-11-06 2020-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for subtyping lymphoma types by means of expression profiling
CN104796448B (zh) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2015184145A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
US20180028531A1 (en) 2015-02-12 2018-02-01 BeyondSpring Phamaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
US20250073230A1 (en) 2015-02-12 2025-03-06 Beyondspring Pharmaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
CN106279039B (zh) 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
AU2016291708B2 (en) 2015-07-13 2020-12-24 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
EP3413885A4 (en) 2016-02-08 2019-09-18 Beyondspring Pharmaceuticals, Inc. COMPOSITIONS WITH TUCARESOL OR ITS ANALOG
SG11201810872UA (en) * 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
JP6779517B2 (ja) 2016-09-02 2020-11-04 国立大学法人 鹿児島大学 抗癌剤の感受性及び癌の予後に対する診断マーカー
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
CA3056077A1 (en) 2017-03-13 2018-09-20 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
KR20200116477A (ko) 2018-02-01 2020-10-12 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 및 g-csf 제제의 투여를 통해 화학요법-유도된 호중구감소증을 감소시키기 위한 조성물 및 방법
CN110240592A (zh) 2018-03-08 2019-09-17 青岛海洋生物医药研究院股份有限公司 (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
JP7372253B2 (ja) 2018-04-05 2023-10-31 ノビガ・リサーチ・エービー 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ
WO2019232257A1 (en) 2018-06-01 2019-12-05 Beyondspring Pharmaceuticals, Inc. Composition and method of treating cancer associated with egfr mutation
CN112638388A (zh) 2018-08-16 2021-04-09 大连万春布林医药有限公司 刺激免疫反应的方法和组合物
WO2020102244A1 (en) 2018-11-14 2020-05-22 Beyondspring Pharmaceuticals, Inc. Methods of treating cancer using tubulin binding agents
JP2022552011A (ja) 2019-10-15 2022-12-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 鉄障害を処置するための方法及び組成物
CN112778155B (zh) 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
IL297884A (en) 2020-05-04 2023-01-01 Beyondspring Pharmaceuticals Inc Triple combination therapy to increase cancer cell killing in cancers with low immunogenicity
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN115703763A (zh) 2021-08-13 2023-02-17 大连万春布林医药有限公司 普那布林或其制剂中的杂质及其用途
EP4412613A4 (en) 2021-10-07 2025-10-22 Beyondspring Pharmaceuticals Inc METHODS OF TREATMENT OF CANCERS AND TUMORS

Also Published As

Publication number Publication date
KR20190109479A (ko) 2019-09-25
PH12019501763A1 (en) 2020-03-16
EP3576733A4 (en) 2020-11-25
RU2019125489A3 (enExample) 2021-10-25
CL2019002127A1 (es) 2019-12-13
BR112019015974A2 (pt) 2020-03-31
IL268305B2 (en) 2024-08-01
JP2022191484A (ja) 2022-12-27
NZ755858A (en) 2021-11-26
MY201811A (en) 2024-03-19
IL268305B1 (en) 2024-04-01
AU2018217120B2 (en) 2024-02-08
US20220378784A1 (en) 2022-12-01
WO2018144764A1 (en) 2018-08-09
MX2022010805A (es) 2022-09-27
CA3052190A1 (en) 2018-08-09
RU2019125489A (ru) 2021-03-02
IL268305A (en) 2019-09-26
US12458638B2 (en) 2025-11-04
US20200038395A1 (en) 2020-02-06
AU2018217120A1 (en) 2019-08-15
EP3576733A1 (en) 2019-12-11
KR20240110997A (ko) 2024-07-16
SG11201907023UA (en) 2019-08-27
US11400086B2 (en) 2022-08-02
CN110381938A (zh) 2019-10-25
JP2020514412A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
MX2022010805A (es) Metodo para reducir la neutropenia.
CL2017002050A1 (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2018004475A (es) Agentes biologicos y su uso en plantas.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MX2020001406A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
CN106659716A8 (zh) 阿吡莫德组合物及其使用方法
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
CL2016002223A1 (es) Microorganismo recombinante que expresa análogos de avermectina y uso de los mismos.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
MX2017015315A (es) Granos de gluten reducido y composiciones de los mismos.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2019008460A (es) Metodos para tratar esclerosis multiple usando celulas t autologas.
AR113514A1 (es) Composiciones y métodos para mejorar la utilización del fósforo y el calcio en la dieta de los animales
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
CL2018003188A1 (es) Procedimiento para la preparación de cuerpos moldeados para la administración a animales.